Key Takeaways
- Strong quarter, conservative guide intact: Revenue and profitability were robust, driven by export formulations, while management reiterated its 20% PAT growth guidance for FY25 and hinted it may do better.
- Revlimid remains the engine, for now: The product is performing well with no challenges expected this fiscal year, but management flagged that FY27 and FY28 will be a challenge as market share and pricing erode.
- The pipeline is a box of high-risk, long-dated bets: The strategy relies on a portfolio of 10-15 ideas like Olaparib, Semaglutide, and eGenesis, where success means 6 or 7 big wins over the next 8-10 years, accepting volatility in between.
- Margins are peaking, investment is front-loaded: R&D spending of nearly INR100-125 crores this quarter weighed on reported expenses, but management expects to sustain current high margins for this year and next.
- What to watch next quarter: The December quarter is expected to be weaker sequentially, and management promised more clarity on FY26 earnings and Revlimid's trajectory after those results.
The Revlimid Cliff: Managing the Transition
- Current performance is solid: Revlimid contribution in Q2 was likely in the same range as Q1, and management expects no challenges for the remainder of this financial year.
- Volume adjustment nearly complete: Most of the volume adjustment is done, with only a small tail left, which partly explains why the December quarter will be weaker than Q2.
- The cliff is visible but unquantified: Management expects to capture one-third of the total market by January, but cannot judge the extent of price erosion next year. They explicitly stated that FY27 and FY28 will be a challenge.
- Clarity is promised, not delivered: Management deferred any concrete view on FY26 Revlimid revenues, saying they will have more clarity after December numbers and again post-March earnings for the following year.
- The post-Revlimid strategy is a patchwork of pipeline and M&A: The plan is to build other products and markets, use cash on the books for an accretive acquisition, and hope that other pipeline assets open up in time.
Rajeev Nannapaneni: "I think the challenge that we face in our business is that we are not consistent. I mean we'll have 3, 4 good years and we'll have 2 years of dip, and again then we'll have to 3 good years again but I think that's the nature of the risk that we take."
Pipeline: A Portfolio of Asymmetric Bets
- The philosophy is venture-capital style: Natco invests in disruptive ideas with a 5-to-8-year horizon, where the payoff is tremendous if the technology works, and the loss is contained if it does not. The eGenesis investment in genetically modified pig organ transplants exemplifies this approach.
- The pipeline is a box of 10-15 ideas: The strategy is to place multiple high-risk bets, knowing that if 6 or 7 work in the next 8-10 years, the outcome is excellent. Current visible bets include Olaparib, Semaglutide, Ibrutinib, Capmatinib, and Erdafitinib.
- Semaglutide is the nearest large opportunity: One formulation is settled with two strengths as sole first-to-file (FTF) and other strengths as shared FTF, while a second formulation is not settled and remains under litigation as a sole FTF. The India opportunity is expected post-2026, after compound expiry.
- Olaparib is stuck in litigation: The filing was moved to a partner site due to a warning letter at the Kothur facility, and a trial date is set about 1-1.5 years from now. Approval depends on the litigation outcome.
- Capmatinib (Tabrecta) is a fresh, high-upside filing: Filed this quarter as a sole FTF eligible for 180 days of exclusivity, and will be marketed by Natco's own U.S. entity, retaining 100% of the economics. The launch timeline depends on litigation clarity.
- Smaller assets fill the gaps: Carfilzomib 10-mg and Bosentan 32-mg are expected in the next few years, while Erdafitinib and Capmatinib are at a very early stage.
Rajeev Nannapaneni: "We never think in terms of near term. we always think about long term. And I think all our ideas are 5 years, 7 years, 8 years away. But I think when they come big."
Financial Performance & Margin Outlook
- Revenue drivers were export-led: Strong growth came primarily from the export formulation business, while the domestic pharma business remained stable but did not grow.
- Reported expenses are inflated by R&D: The quarter absorbed nearly INR100-125 crores in R&D spending, bio-studies, and exhibit batches, which overstates the underlying cost structure. Management argued that R&D spend is a function of having a big product, and expenses would reduce if profits fell.
- Margin sustainability looks good for two years: Management expects to maintain the current margin profile, which is around 60%, for this fiscal year and FY26.
- PAT guidance is conservative: On a trailing-twelve-month basis, PAT growth is already at 40%, against a guided 20%. Management acknowledged they have been conservative and should do better.
- Subsidiaries are stable but small: All subsidiaries together did INR120 crores of top line, and management expects things to remain stable, though they could not provide a YoY comparison.
- Crop protection is a drag, with a breakeven timeline: Sales were lower because the previous year was the first full year of operations and required adjustments for returns. The business is expected to break even starting from March 2026.
Rajeev Nannapaneni: "if you don't have a big product, then you can't spend on R&D also, so then the expenses also get reduced by that much. I mean you can't say that I'll spend like a lot of money, but I don't have a profit. You only spend if you make the money. Both are interlinked, right?"
Domestic & Emerging Markets: Waiting for a Catalyst
- Domestic business is stagnant without launches: The business has been stable but has not grown, and management was explicit that without a pipeline of backward-integrated, own-manufactured products, there is no margin or growth.
- Semaglutide is the hoped-for jump-start: Management expects the domestic business to compound at 15-20% over a 2-3 year perspective once Semaglutide launches in India, which is expected post-2026 after compound expiry and regulatory approval.
- India market dynamics are uncertain: Supply from the innovator has been limited, so the true market size is unknown. Once Indian generics launch, pricing will be competitive, and enough competition is expected.
- Emerging markets are an organic and inorganic build: Natco is looking at a couple of acquisitions in the rest-of-world business while also building organically.
- M&A appetite is broad and cash-backed: Management is open to transactions of any size, and the cash on the balance sheet provides flexibility to do something large, though nothing has been closed.
Rajeev Nannapaneni: "Without pipeline, you have nothing. And you need to have pipeline where you're backward integrated doing your own manufacturing, only then you have margin. Otherwise, there is no margin also."
Strategy & Business Model Conviction
- Management rejects the commodity generics model: The view is that me-too generic portfolios, where every player files everything across every geography, cannot generate earnings growth. Natco's model is built on first-wave, limited-competition opportunities.
- Volatility is accepted as structural: The business is explicitly not designed for consistency. Management expects cycles of 3-4 good years followed by 2 years of dip, and frames this as the nature of the risk they take.
- The U.S. generics market rewards portfolio breadth: Good portfolio breadth and first-wave generics drive profitability, and a new pipeline is what sustains it.
- Long-term idea generation is the core competency: The strategy is to maintain a box of 10-15 high-risk, large-payoff ideas, knowing that not all will work. Success is defined as pulling off 6 or 7 ideas in the next 8-10 years.
Rajeev Nannapaneni: "So even if you're able to pull off 6 or 7 ideas in the next 8 to 10 years, I think you have done a great job."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| PAT growth | 20% growth over last year; management says they have been conservative and should do better | FY25 |
| Margin sustainability | Maintain current margin profile (~60%) for this year and next year | FY25 and FY26 |
| December quarter | Will be weaker than Q2; some tail left from volume adjustment | Q3 FY25 |
| Crop protection breakeven | Business expected to break even | Starting March 2026 |
| Revlimid market share | Expect to capture one-third of total market | By January |
| Revlimid clarity | More clarity on next year's performance | Post-December results / post-March earnings |
| Semaglutide India launch | Regulatory approval and launch expected post-compound expiry | Post-2026, by FY27 |
| Domestic business growth | Expect business to compound at 15-20% over a 2-3 year perspective, driven by Semaglutide | 2-3 year perspective |
| Olaparib litigation | Trial date set | 1-1.5 years from now |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Consolidated total revenue | ₹1,434.9 cr, growth of 35.3% YoY vs ₹1,060.8 cr |
| Consolidated net profit | ₹676.5 cr, growth of about 82% YoY vs ₹369 cr |
| Operating margin | 60%, expected to be maintained this year and next year |
| R&D spend (bio-studies and exhibit batches) | ₹100–125 cr in the quarter |
| Second interim dividend | ₹1.5 per equity share declared for FY25 |
| FY25 PAT growth guidance | 20% growth over last year, management indicated conservative and may do better |
| Subsidiaries top line | ₹120 cr contributed by all subsidiaries combined |
| Domestic formulation business outlook | Expected to compound at 15–20% over 2–3 years |
| Crop protection business annual loss | ₹40–50 cr per year, targeting breakeven by March '26 |
| Semaglutide patent expiry timeline | Patents expiring in '31, '33, and '35 |
| Olaparib economics | 50-50 profit share with Alembic |
| Tabrecta (capmatinib) market size | $11–12 million product, sole FTF with 100% economics retained |
| Potential cash by FY26 | $400–500 million |
| Acquisition transaction range under evaluation | $3 million to $300 million range |